Introduction
ARA-290, also known as Cibinetide, is a synthetic peptide that has been gaining attention in the medical and scientific communities for its potential therapeutic applications. This peptide, developed by Araim Pharmaceuticals, is composed of 11 amino acids and is entirely derived from the helix beta domain of erythropoietin (EPO), a glycoprotein hormone naturally produced by the peritubular cells of the kidney that stimulates red blood cell production1.
Erythropoietin is primarily known for its role in promoting the production of red blood cells, a process known as erythropoiesis. However, researchers have discovered that EPO and its derivatives, like ARA-290, can also have other beneficial effects, such as anti-inflammatory and tissue-protective actions1.
Mechanism of Action
The development of ARA-290 was driven mainly by Araim Pharmaceuticals’ discovery of the Innate Repair Receptor (IRR), a receptor that plays a crucial role in reducing chronic inflammation and promoting tissue repair. Interestingly, EPO naturally binds to the IRR and activates several anti-inflammatory pathways1.
ARA-290, being derived from EPO, also binds to the IRR. However, unlike EPO, ARA-290 does not stimulate erythropoiesis, which means it does not carry the risk of causing excessive red blood cell production, a potential side effect of EPO. This makes ARA-290 a more targeted and safer option for therapeutic applications that leverage the anti-inflammatory and tissue-protective effects of EPO1.
Benefits of ARA-290
Pain Management
One of the most promising potential applications of ARA-290 is in the management of severe levels of pain. Chronic pain is a significant health issue linked to numerous physical and mental conditions and contributes to high healthcare costs and lost productivity1.
ARA-290 has shown promise in preclinical and clinical studies for its potential to alleviate severe pain levels. This is believed to be due to its ability to reduce inflammation and promote the repair of damaged tissues, which can help to alleviate the underlying causes of chronic pain1.
Lowering Chronic Inflammation
Chronic inflammation is a common feature of many diseases and health conditions, including autoimmune diseases, heart disease, diabetes, and even cancer. By binding to the IRR and activating anti-inflammatory pathways, ARA-290 has the potential to help lower chronic inflammation, which could have wide-ranging benefits for health and disease management1.
Restoring Health Markers in Diabetic Patients
Diabetes is a major health issue that affects millions of people worldwide. It is characterized by high blood sugar levels, which can damage various tissues and organs in the body over time. ARA-290 is currently in Phase II clinical trials for treating diabetic neuropathy, a condition that affects the nerves in people with diabetes1.
In addition to its potential to alleviate neuropathic pain, ARA-290 has also shown promise in improving other health markers in diabetic patients. For example, patients receiving ARA-290 improvements in hemoglobin A1c (HbA1c), a feature of blood sugar control, and lipid profiles, which are important for cardiovascular health1.
Nerve Repair and Regeneration
Damage to the nerves, whether due to injury or diseases like diabetes, can lead to chronic pain, loss of sensation, and other problems. ARA-290 has demonstrated significant nerve regrowth assessed by two different measures of nerve fiber regeneration, as well as reductions in pain and functional capacity2.
This suggests that ARA-290 could potentially be used to promote nerve repair and regeneration, which could be beneficial for conditions like diabetic neuropathy, nerve injuries, and other conditions that involve nerve damage2.
Side Effects and Safety Profile
As with any medication or therapeutic agent, it’s important to consider the potential side effects and safety profile of ARA-290. So far, no significant safety issues have been observed in the clinical trials conducted on ARA-2901.
However, it’s important to note that ARA-290 is still in the clinical trial phase, and more research is needed to fully understand its safety profile. As always, any potential treatment should be discussed with a healthcare provider to weigh the potential benefits against the potential risks1.
Mixing and Solubility of ARA-290
When preparing ARA-290 for use, it’s important to note that this peptide is soluble in alkaline solutions. This means that when it’s mixed with bacteriostatic water (Bac water), it may appear cloudy. This is a normal characteristic of the peptide and does not indicate any product quality or effectiveness issue [^5^].
This information is confirmed by MedChemExpress, a reputable source for biochemical compounds[^5^]. It’s also been noted by labs that ARA-290 can be a bit challenging to handle due to its solubility properties. However, this does not affect its potential benefits or uses[^5^].
Where to Buy ARA-290
Currently, ARA-290 is still in the middle of clinical trials and is not available for general purchase. It is recognized by the FDA as an orphan drug for the treatment of sarcoidosis-induced neuropathic pain1. As research continues, we can hope for more definitive results on its efficacy and safety, and potentially see it become more widely available in the future.
Conclusion
ARA-290 or Cibinetide is a promising peptide with potential benefits in pain management, lowering chronic inflammation, restoring health markers in diabetic patients, and nerve repair and regeneration. Its unique solubility properties in alkaline solutions, confirmed by MedChemExpress1, make it a peptide of interest in the scientific community. However, it’s important to note that it’s still in the clinical trial phase and not yet available for general use. As research continues, we can hope for more definitive results on its efficacy and safety.
